ARIAD Announces Appointment of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, as Chief Legal & Administrative O...
January 22 2015 - 7:35AM
Business Wire
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the
appointment of Thomas J. DesRosier, Esq. to the position of
executive vice president, chief legal and administration officer,
and secretary. Mr. DesRosier will be responsible for global legal
operations, information technology and other administrative
functions. He will report to ARIAD’s chairman and chief executive
officer, Harvey J. Berger, M.D.
Thomas J. DesRosier, Esq. joins ARIAD as
executive vice president, chief legal and administration officer,
and secretary. (Photo: Business Wire)
Mr. DesRosier has more than 30 years of global biotechnology and
pharmaceutical industry experience and joins ARIAD from Cubist
Pharmaceuticals, Inc., where he held the same position as the one
he will assume at ARIAD. Prior to Cubist, Mr. DesRosier was senior
vice president, general counsel, North America of Sanofi, a
position he assumed following the acquisition of Genzyme
Corporation by Sanofi in 2011, where he had served as Genzyme’s
senior vice president, chief legal officer.
“Mr. DesRosier is a talented and experienced attorney, who has
had a stellar career in the pharmaceutical and biotechnology
industries,” stated Dr. Berger. “We are excited to welcome Tom to
ARIAD, and I look forward to working closely with him as we make
the transition to a profitable oncology company over the next three
years. I expect Tom to have a positive impact on the Company in
many areas immediately upon joining our leadership team.”
Prior to his 12-year tenure at Genzyme, Mr. DesRosier held a
number of senior legal positions at Wyeth Pharmaceuticals, Genetics
Institute, and E.I. DuPont de Nemours. He received his J.D. from
Wake Forest University School of Law and his B.A. degree in
Chemistry from the University of Vermont.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an integrated global
oncology company focused on transforming the lives of cancer
patients with breakthrough medicines. ARIAD is working on new
medicines to advance the treatment of various forms of chronic and
acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer
medicines. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter
(@ARIADPharm).
This press release contains “forward-looking statements” which
are based on management's good-faith expectations and are subject
to certain factors, risks and uncertainties that may cause actual
results, outcome of events, timing and performance to differ
materially from those expressed or implied by such statements.
These factors, risks and uncertainties include, but are not limited
to our ability to execute on our corporate strategies for
profitability; our ability to successfully commercialize and
generate profits from sales of our products; competition from
alternative therapies, our reliance on the performance of
third-party manufacturers and specialty pharmacies for the
distribution of Iclusig; preclinical data and early-stage clinical
data that may not be replicated in later-stage clinical studies,
the costs associated with our research, development, manufacturing
and other activities, the enrollment, conduct, timing and results
of pre-clinical and clinical studies of our product candidates, the
adequacy of our capital resources and the availability of
additional funding, and other factors detailed in the Company's
public filings with the U.S. Securities and Exchange Commission.
The information contained in this press release is believed to be
current as of the date of original issue. After the date of this
document, the Company does not intend to update any of the
forward-looking statements to conform these statements to actual
results or to changes in the Company's expectations, except as
required by law.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20150122005041/en/
ARIAD Pharmaceuticals, Inc.For InvestorsKendra Adams,
617-503-7028Kendra.adams@ariad.comorFor MediaLiza Heapes,
617-621-2315Liza.heapes@ariad.com
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Sep 2023 to Sep 2024